CFDB - Cystic Fibrosis DataBase

primary studies congress abstract

Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study


Pneumologie (Stuttgart, Germany), 2019, 73(SUPPPL. 1)

Keywords: Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; lumacaftor; Orkambi; Symdeko; Symkevi;